Mesoridazine
From Wikipedia, the free encyclopedia
| Image:Mesoridazine.png | |
| Mesoridazine
| |
| Systematic (IUPAC) name | |
| 10-[2-(1-methyl-2-piperidyl)ethyl] -2-methylsulfinyl-10H-phenothiazine | |
| Identifiers | |
| CAS number | 5588-33-0 |
| ATC code | N05AC03 |
| PubChem | 4078 |
| DrugBank | APRD00610 |
| Chemical data | |
| Formula | C21H26N2OS2 |
| Mol. weight | 386.576 g/mol |
| Pharmacokinetic data | |
| Bioavailability | ? |
| Protein binding | 4% |
| Metabolism | Hepatic/Renal |
| Half life | 24 to 48 hours |
| Excretion | Biliary/Renal |
| Therapeutic considerations | |
| Pregnancy cat. |
C (USA) |
| Legal status |
℞ Prescription only |
| Routes | oral, intravenous |
Serentil® (mesoridazine besylate) is a neuroleptic drug that is used in the treatment of schizophrenia, organic brain disorders, psychoneuroses, and alcoholism. It is the besylate salt of a metabolite of thioridazine. It exerts its actions through a central adrenergic-blocking, a dopamine-blocking, a serotonin-blocking, and a weak anticholinergic action. It also exerts part of its actions through depression of hypothalamic centers, like other phenothiazines.

